BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22996376)

  • 41. Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.
    Guo Y; Jia L; Shao GG; Sun HW; Wang XX; Wang GJ; Ma KW
    J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):350-355. PubMed ID: 26072072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
    Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
    BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients.
    Morodomi Y; Okamoto T; Takenoyama M; Takada K; Katsura M; Suzuki Y; Fujishita T; Kitahara H; Shimamatsu S; Kohno M; Tagawa T; Okano S; Taguchi K; Ichinose Y; Maehara Y
    Ann Surg Oncol; 2015 Aug; 22(8):2593-8. PubMed ID: 25373537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.
    Bacchi CE; Ciol H; Queiroga EM; Benine LC; Silva LH; Ojopi EB
    Clinics (Sao Paulo); 2012; 67(5):419-24. PubMed ID: 22666783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR and KRAS mutations in patients with adenocarcinoma of the lung.
    Jang TW; Oak CH; Chang HK; Suo SJ; Jung MH
    Korean J Intern Med; 2009 Mar; 24(1):48-54. PubMed ID: 19270482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
    Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
    J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
    Folch E; Yamaguchi N; VanderLaan PA; Kocher ON; Boucher DH; Goldstein MA; Huberman MS; Kent MS; Gangadharan SP; Costa DB; Majid A
    J Thorac Oncol; 2013 Nov; 8(11):1438-1444. PubMed ID: 24128714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
    Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
    Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung.
    Stigt JA; 'tHart NA; Knol AJ; Uil SM; Groen HJ
    J Thorac Oncol; 2013 Aug; 8(8):1012-8. PubMed ID: 23807543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
    Schneider F; Derrick V; Davison JM; Strollo D; Incharoen P; Dacic S
    Mod Pathol; 2016 Jul; 29(7):735-42. PubMed ID: 27080983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer.
    Tam KW; Zhang W; Soh J; Stastny V; Chen M; Sun H; Thu K; Rios JJ; Yang C; Marconett CN; Selamat SA; Laird-Offringa IA; Taguchi A; Hanash S; Shames D; Ma X; Zhang MQ; Lam WL; Gazdar A
    J Thorac Oncol; 2013 Nov; 8(11):1378-88. PubMed ID: 24077454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.
    Hoque MO; Brait M; Rosenbaum E; Poeta ML; Pal P; Begum S; Dasgupta S; Carvalho AL; Ahrendt SA; Westra WH; Sidransky D
    J Thorac Oncol; 2010 Dec; 5(12):1887-93. PubMed ID: 21102258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
    Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
    Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 59. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
    Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
    Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation.
    Suzuki M; Shigematsu H; Hiroshima K; Iizasa T; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Hum Pathol; 2005 Oct; 36(10):1127-34. PubMed ID: 16226114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.